Skip navigation
Full metadata record
DC FieldValueLanguage
dc.contributor.authorEconomides, Nicholas - NYU Stern School of Business-
dc.contributor.authorLianos, Ioannis - University College London-
dc.date.accessioned2010-11-10T05:13:51Z-
dc.date.available2010-11-10T05:13:51Z-
dc.date.issued2010-
dc.identifier.urihttp://hdl.handle.net/2451/29850-
dc.description.abstractWe discuss and compare the remedies from the European Union’s two cases against Microsoft. The first E.U. case ("E.U. Microsoft I") alleged that Microsoft illegally bundled the Windows Media Player with Windows and that Microsoft did not provide adequate documentation that would allow full interoperability between Windows servers and non- Microsoft servers, as well as between Windows clients and non-Microsoft servers. After finding Microsoft liable and imposing a large fine, the E.U. imposed as remedies two requirements on Microsoft: (1) to sell a version of Windows without Windows Media Player ("Windows-N") and (2) to publish and license interoperability information. Windows-N was a commercial failure, and there has been only limited cross-platform server entry. In its second investigation of Microsoft ("E.U. Microsoft II"), the E.U. alleged illegal tying of Internet Explorer with Windows. The E.U. settled with Microsoft by having them accept the "choice screen proposal": an obligation to ask consumers whose computers have Internet Explorer pre-installed to choose a browser from a menu of competing browsers through compulsory Windows updates. Thus, the E.U. imposed quite different remedies in the two cases: an unbundling remedy for the Windows Media Player but close to a must-carry requirement for Internet Explorer. We analyze and compare the different approaches.en
dc.relation.ispartofseriesNET Institute Working Paper;09-29-
dc.titleA Critical Appraisal of Remedies in the EU Microsoft Casesen
Appears in Collections:NET Institute Working Papers Series

Files in This Item:
File Description SizeFormat 
Economides_Lianos_09-29.pdfEconomides_Lianos_09-29332.08 kBAdobe PDFView/Open


Items in FDA are protected by copyright, with all rights reserved, unless otherwise indicated.